



Vicore Pharma appoints Erik Penser Bank as Certified Adviser

Vicore Pharma AB (publ) has entered into an agreement with Erik Penser Bank regarding the service as Certified Adviser. Erik Penser Bank will be appointed Certified Adviser from June 1, 2017.

For further information, please contact

Per Jansson, CEO

Tel: +46 709 17 47 46 or e-mail: per.jansson@vicorepharma.com

This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication May 24, 2017 at 09:00 CET.

About Vicore Pharma Holding

Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopathic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com

*Vicore Pharms share is listed on NASDAQ Stockholm, First North under the ticker VICO.
The company's Certified Adviser is Redeye AB.*